Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use or CHMP has recommended a marketing authorization for Glaxo Group's Volibris, 5mg and 10mg, film coated tablets intended for treatment of pulmonary arterial hypertension.
Subscribe to our email newsletter
The active substance of Volibris is ambrisentan, an anti-hypertensives medicinal product (C02KX02). Volibris is indicated for the treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.